Valeria Vangeli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valeria Vangeli has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Mastroianni
Infectious & Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy
15 shared publications - Sonia Greco
Infectious & Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy
14 shared publications - Maria Vittoria Mauro
Microbiology Unit, “Annunziata” Hub Hospital, Azienda Ospedaliera di Cosenza, 87100 Cosenza, Italy
9 shared publications - Francesca Greco
Microbiology Unit, “Annunziata” Hub Hospital, Azienda Ospedaliera di Cosenza, 87100 Cosenza, Italy
8 shared publications - Giuliana Guadagnino
Infectious & Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy
6 shared publications - Antonio Mori
Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Italy
5 shared publications
Latest Publications
- 29 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 21, 1-6
Efficacy and Safety of Sequential Combined Immunomodulatory Systemic Therapies Used in the Management of Refractory Cytokine Release Syndrome in Critically Ill Patients with COVID-19
Introduction/Objective: Severe Coronavirus Disease 2019 (COVID-19) is characterized by systemic hyperinflammation and cytokine storm, a series of clinical conditions caused by excessive immune reactions. Although numerous studies have been conducted on anti-inflammatory treatments for severe COVID-19, no specific recommendations have been made regarding drugs to use in patients with Refractory Cytokine Release Syndrome (CRS) after the use of first-line anticytokine drugs. The objective of this report was to evaluate the efficacy of sequential immunomodulatory therapies in the management of refractory CRS in COVID-19 patients. Methods: From March 2020 to March 2023, 1,025 patients with COVID-19 were admitted to the Infectious and Tropical Diseases ward at the Annunziata Cosenza Hub Hospital in Cosenza, Italy. To determine how many patients with refractory COVID-19-associated CRS were treated with combinedsequential therapy involving tocilizumab, a recombinant humanized anti-Interleukin-6 (IL-6) receptor monoclonal antibody, and baricitinib, a Janus kinase inhibitor, or anakinra, a recombinant human interleukin- 1 receptor antagonist, the electronic medical records of all hospitalized patients with COVID-19 were reviewed. The primary outcome was the incidence of CRS by day 29. Secondary outcomes included in-hospital mortality and 30-day mortality, to assess hospital performance and patient safety. Electronic databases such as MEDLINE, EMBASE, and Cochrane Central were searched through June 30, 2026, for case-series and studies evaluating the efficacy of sequential combined immunomodulatory systemic therapies in the management of refractory CRS in critically ill patients with COVID-19. Results: From January 2021 to December 2023, a total of 25 patients received sequential combined immunomodulatory systemic therapies, including tocilizumab and baricitinib or anakinra, in the management of COVID-19-related CRS. After 72 hours from the introduction of the new anti-cytokine therapy, a significant improvement of respiratory parameters, clinical state, inflammatory markers, and blood counts was observed. All patients survived, and those 5 previously mechanically ventilated patients were extubated. Non-infectious or infectious pulmonary or systemic complications were observed in all patients who underwent sequential combined immunomodulatory systemic therapies. Discussion: The study’s findings suggest that tocilizumab used in sequential combination with baricitinib or anakinra, in conjunction with standard of care treatments, was associated with improved outcomes in critically ill patients with COVID-19 disease and early discharge from the hospital. Conclusion: There is clear rationale for using combined immunomodulatory systemic therapies in critically ill patients who develop refractory CRS. The results of the experience, supported by a review of the current literature, suggest the need for larger-scale studies on sequential and combined systemic immunomodulatory therapies to manage refractory CRS in critically ill patients with COVID-19.
- 29 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 21, 1-6
Efficacy and Safety of Sequential Combined Immunomodulatory Systemic Therapies Used in the Management of Refractory Cytokine Release Syndrome in Critically Ill Patients with COVID-19
Introduction/Objective: Severe Coronavirus Disease 2019 (COVID-19) is characterized by systemic hyperinflammation and cytokine storm, a series of clinical conditions caused by excessive immune reactions. Although numerous studies have been conducted on anti-inflammatory treatments for severe COVID-19, no specific recommendations have been made regarding drugs to use in patients with Refractory Cytokine Release Syndrome (CRS) after the use of first-line anticytokine drugs. The objective of this report was to evaluate the efficacy of sequential immunomodulatory therapies in the management of refractory CRS in COVID-19 patients. Methods: From March 2020 to March 2023, 1,025 patients with COVID-19 were admitted to the Infectious and Tropical Diseases ward at the Annunziata Cosenza Hub Hospital in Cosenza, Italy. To determine how many patients with refractory COVID-19-associated CRS were treated with combinedsequential therapy involving tocilizumab, a recombinant humanized anti-Interleukin-6 (IL-6) receptor monoclonal antibody, and baricitinib, a Janus kinase inhibitor, or anakinra, a recombinant human interleukin- 1 receptor antagonist, the electronic medical records of all hospitalized patients with COVID-19 were reviewed. The primary outcome was the incidence of CRS by day 29. Secondary outcomes included in-hospital mortality and 30-day mortality, to assess hospital performance and patient safety. Electronic databases such as MEDLINE, EMBASE, and Cochrane Central were searched through June 30, 2026, for case-series and studies evaluating the efficacy of sequential combined immunomodulatory systemic therapies in the management of refractory CRS in critically ill patients with COVID-19. Results: From January 2021 to December 2023, a total of 25 patients received sequential combined immunomodulatory systemic therapies, including tocilizumab and baricitinib or anakinra, in the management of COVID-19-related CRS. After 72 hours from the introduction of the new anti-cytokine therapy, a significant improvement of respiratory parameters, clinical state, inflammatory markers, and blood counts was observed. All patients survived, and those 5 previously mechanically ventilated patients were extubated. Non-infectious or infectious pulmonary or systemic complications were observed in all patients who underwent sequential combined immunomodulatory systemic therapies. Discussion: The study’s findings suggest that tocilizumab used in sequential combination with baricitinib or anakinra, in conjunction with standard of care treatments, was associated with improved outcomes in critically ill patients with COVID-19 disease and early discharge from the hospital. Conclusion: There is clear rationale for using combined immunomodulatory systemic therapies in critically ill patients who develop refractory CRS. The results of the experience, supported by a review of the current literature, suggest the need for larger-scale studies on sequential and combined systemic immunomodulatory therapies to manage refractory CRS in critically ill patients with COVID-19.
- 19 April 2026
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 32 (3) , 14
Journal of neurovirology
- 19 April 2026
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 32 (3) , 14
Journal of neurovirology
- Open Access
- 1 March 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (4) , 1075-1092
Oritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study
Introduction The management of complicated Gram-positive bloodstream infections (cBSI) and infective endocarditis (IE) often requires prolonged intravenous therapy. Transition to oral therapy is frequently unfeasible because of resistance, drug interactions, or adherence concerns, increasing the risk of intravenous-related complications and healthcare burden. The pharmacokinetic profile and spectrum of oritavancin may enable effective treatment and early discharge. This study evaluated its effectiveness, safety, and impact on hospital resource use in patients with cBSI or IE. Methods We conducted a multicenter, retrospective, observational study across eight hospitals in Italy and Spain (April 2023–February 2025). Adult patients with Gram-positive cBSI (persistent/refractory BSI or prosthetic material) or IE (2023 modified Duke criteria) treated with ≥ 1 dose of oritavancin were included. Dosing was determined by the treating physicians. Data on outcomes, adverse events (AEs) and healthcare use were collected from medical records. Patients were followed for at least 6 months. Results Twenty-seven patients were included: 13 (48.1%) cBSI and 14 (51.9%) IE. Median age was 73 years (IQR 65–81); 18 out of 27 (66.7%) were male; Charlson Comorbidity Index 6 (IQR 4–7). In cBSI, oritavancin was first-line in 6/13 (46.2%) and given in multiple doses in 8/13 (61.6%), median of 2 doses (IQR 2–2.5). Clinical success was 100%, with no recurrence or BSI-related mortality. In IE, Staphylococcus aureus was identified in 5 of 14 cases (35.7%), of which 40% were methicillin-resistant. Native valves were involved in 6/14 (42.8%), prosthetic valves in 6/14 (42.8%), cardiac devices in 2/14 (14.3%). Clinical success was achieved in 85.7% of patients with IE (12/14). Two AEs occurred: nausea and a non-fatal acute coronary syndrome in a patient with pre-existing ischemic heart disease. Oritavancin use reduced 369 hospital days with potential savings of approximately €4235 per patient. Conclusions Oritavancin may represent a safe, effective treatment option for selected patients with cBSI or IE, with advantages in outcomes, reduced hospital stay, and cost containment.
- 1 March 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (4) , 1075-1092
Open AccessOritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study
Introduction The management of complicated Gram-positive bloodstream infections (cBSI) and infective endocarditis (IE) often requires prolonged intravenous therapy. Transition to oral therapy is frequently unfeasible because of resistance, drug interactions, or adherence concerns, increasing the risk of intravenous-related complications and healthcare burden. The pharmacokinetic profile and spectrum of oritavancin may enable effective treatment and early discharge. This study evaluated its effectiveness, safety, and impact on hospital resource use in patients with cBSI or IE. Methods We conducted a multicenter, retrospective, observational study across eight hospitals in Italy and Spain (April 2023–February 2025). Adult patients with Gram-positive cBSI (persistent/refractory BSI or prosthetic material) or IE (2023 modified Duke criteria) treated with ≥ 1 dose of oritavancin were included. Dosing was determined by the treating physicians. Data on outcomes, adverse events (AEs) and healthcare use were collected from medical records. Patients were followed for at least 6 months. Results Twenty-seven patients were included: 13 (48.1%) cBSI and 14 (51.9%) IE. Median age was 73 years (IQR 65–81); 18 out of 27 (66.7%) were male; Charlson Comorbidity Index 6 (IQR 4–7). In cBSI, oritavancin was first-line in 6/13 (46.2%) and given in multiple doses in 8/13 (61.6%), median of 2 doses (IQR 2–2.5). Clinical success was 100%, with no recurrence or BSI-related mortality. In IE, Staphylococcus aureus was identified in 5 of 14 cases (35.7%), of which 40% were methicillin-resistant. Native valves were involved in 6/14 (42.8%), prosthetic valves in 6/14 (42.8%), cardiac devices in 2/14 (14.3%). Clinical success was achieved in 85.7% of patients with IE (12/14). Two AEs occurred: nausea and a non-fatal acute coronary syndrome in a patient with pre-existing ischemic heart disease. Oritavancin use reduced 369 hospital days with potential savings of approximately €4235 per patient. Conclusions Oritavancin may represent a safe, effective treatment option for selected patients with cBSI or IE, with advantages in outcomes, reduced hospital stay, and cost containment.
- Open Access
- 27 February 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (5) , 607
West Nile Virus Lineage 2 Neuroinvasive Infection Presenting as Intraparenchimal Cerebral Hemorrage
Objective: The aim of this retrospective study was to evaluate clinical and laboratory characteristics in adult patients with neuroinvasive West Nile virus (WNDD). We also studied the phylogeny and molecular characteristics of some of the WNV strains. Methods: A retrospective analysis was conducted at “Annunziata” Hub Hospital, a secondary referral facility in Calabria region, in Southern Italy. Sample pre-processing, sequencing and bioinformatic analyses were carried out at IRCCS Sacro Cuore Don Calabria Hospital in Negrar di Valpolicella, Verona, Veneto region in North-East Italy. Results: Nine cases of WNDD were analyzed, involving eight males and one female, with a mean age of 70.33 years (range 60–85). The overall average hospital stay was 20.6 days (range 6–46). Six patients made a full recovery after a mean of 35.3 days of acute care. Thirty-day mortality rate was 23%. VNDD in some of our patients manifested itself in the form of cerebral hemorrhage (ICH) in three patients, causing lethality in two patients and other unusual manifestations, such as Guillain–Barré syndrome with fatal outcome and severe facial palsy. Phylogenetic analysis shows that our sequences are closely related to other southern-Italian and cluster with Central–Southern–Eastern European sequences, while being evidently separated from northern Italian and Central–Western European ones, belonging to the sub-lineage 2a of the WNV-2, clustering with sequences from the Central–South–Eastern clade, mainly to Hungary. Conclusions: Cerebrovascular complications of WNE may be an important clinical manifestation of WNV neuroinvasive infection. Preliminary data do not allow us to determine whether our strains, closely related to other southern-Italian and cluster with Central–Southern–Eastern European sequences, really presented an increased neurovirulence.
- 27 February 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (5) , 607
Open AccessWest Nile Virus Lineage 2 Neuroinvasive Infection Presenting as Intraparenchimal Cerebral Hemorrage
Objective: The aim of this retrospective study was to evaluate clinical and laboratory characteristics in adult patients with neuroinvasive West Nile virus (WNDD). We also studied the phylogeny and molecular characteristics of some of the WNV strains. Methods: A retrospective analysis was conducted at “Annunziata” Hub Hospital, a secondary referral facility in Calabria region, in Southern Italy. Sample pre-processing, sequencing and bioinformatic analyses were carried out at IRCCS Sacro Cuore Don Calabria Hospital in Negrar di Valpolicella, Verona, Veneto region in North-East Italy. Results: Nine cases of WNDD were analyzed, involving eight males and one female, with a mean age of 70.33 years (range 60–85). The overall average hospital stay was 20.6 days (range 6–46). Six patients made a full recovery after a mean of 35.3 days of acute care. Thirty-day mortality rate was 23%. VNDD in some of our patients manifested itself in the form of cerebral hemorrhage (ICH) in three patients, causing lethality in two patients and other unusual manifestations, such as Guillain–Barré syndrome with fatal outcome and severe facial palsy. Phylogenetic analysis shows that our sequences are closely related to other southern-Italian and cluster with Central–Southern–Eastern European sequences, while being evidently separated from northern Italian and Central–Western European ones, belonging to the sub-lineage 2a of the WNV-2, clustering with sequences from the Central–South–Eastern clade, mainly to Hungary. Conclusions: Cerebrovascular complications of WNE may be an important clinical manifestation of WNV neuroinvasive infection. Preliminary data do not allow us to determine whether our strains, closely related to other southern-Italian and cluster with Central–Southern–Eastern European sequences, really presented an increased neurovirulence.
- Open Access
- 13 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1809
Introduction of a European Central-South-Eastern West Nile Virus Lineage 2 Strain in Italy in 2023: Evidence from the First Locally Acquired Neuroinvasive Case in the Calabria Region
West Nile virus lineage 2 (WNV-2) is a growing public health concern in Europe causing West Nile fever or West Nile neuroinvasive disease (WNND) with substantial morbidity and mortality; however, genomic data from southern Italy are limited despite recent expansion of autochthonous transmission. The aim of the study was to characterize the phylogenetic and molecular features of the WNV-2 strain responsible for the first autochthonous human infection reported in Calabria (2023), and two more additional WNND cases detected in 2024. Full WNV-2 genomes were generated from the three cases. Phylogenetic analysis was performed using all publicly available WNV sequences up to September 2025. Amino acid changes in the polyprotein were compared with known WNV-2 lineage and sub-lineage signatures. The three sequences formed a monophyletic group within sub-lineage WNV-2a, clustering with strains circulating in Central-South-Eastern Europe and showing closest affinity to Hungarian sequences. Non-synonymous substitutions characteristic of the Hungary 578/10 strain (NS2B-119I, NS4B-14G, NS4B-49A, and NS5-298A) were identified and were absent from Central-Northern-Western European and previously reported Italian sequences. Additional substitutions (E-159T, E-399R, and NS3-249P) corresponded to signatures from a fatal WNV-2 infection in a Great Grey Owl in Slovakia. Our study provides the first report of Central-South-Eastern European WNV-2 circulation outside Eastern Europe, supporting its likely spread through the Balkans into Italy by 2022. These findings underscore the rapid spread of WNV-2 in newly affected areas and highlight the critical need for sustained molecular surveillance.
- 13 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1809
Open AccessIntroduction of a European Central-South-Eastern West Nile Virus Lineage 2 Strain in Italy in 2023: Evidence from the First Locally Acquired Neuroinvasive Case in the Calabria Region
West Nile virus lineage 2 (WNV-2) is a growing public health concern in Europe causing West Nile fever or West Nile neuroinvasive disease (WNND) with substantial morbidity and mortality; however, genomic data from southern Italy are limited despite recent expansion of autochthonous transmission. The aim of the study was to characterize the phylogenetic and molecular features of the WNV-2 strain responsible for the first autochthonous human infection reported in Calabria (2023), and two more additional WNND cases detected in 2024. Full WNV-2 genomes were generated from the three cases. Phylogenetic analysis was performed using all publicly available WNV sequences up to September 2025. Amino acid changes in the polyprotein were compared with known WNV-2 lineage and sub-lineage signatures. The three sequences formed a monophyletic group within sub-lineage WNV-2a, clustering with strains circulating in Central-South-Eastern Europe and showing closest affinity to Hungarian sequences. Non-synonymous substitutions characteristic of the Hungary 578/10 strain (NS2B-119I, NS4B-14G, NS4B-49A, and NS5-298A) were identified and were absent from Central-Northern-Western European and previously reported Italian sequences. Additional substitutions (E-159T, E-399R, and NS3-249P) corresponded to signatures from a fatal WNV-2 infection in a Great Grey Owl in Slovakia. Our study provides the first report of Central-South-Eastern European WNV-2 circulation outside Eastern Europe, supporting its likely spread through the Balkans into Italy by 2022. These findings underscore the rapid spread of WNV-2 in newly affected areas and highlight the critical need for sustained molecular surveillance.
- Open Access
Introduction of a European Central-South-Eastern West Nile Virus Lineage 2 strain in Italy in 2023: evidence from the first locally acquired neuroinvasive case in the Calabria region
Objective: West Nile virus lineage 2 (WNV-2) is a growing public health concern in Europe causing West Nile fever or West Nile neuroinvasive disease (WNND) with substantial morbidity and mortality; however, genomic data from Southern Italy are limited despite recent expansion of autochthonous transmission. The aim of the study was to characterise the phylogenetic and molecular features of the WNV-2 strain responsible for the first autochthonous human infection reported in Calabria (2023), and two more additional WNND cases detected in 2024. Methods: Full WNV-2 genomes were generated from the three cases. Phylogenetic analysis was performed using all publicly available WNV sequences up to September 2025. Amino-acid changes in the polyprotein were compared with known WNV-2 lineage and sub-lineage signatures. Results: The three sequences formed a monophyletic group within sub-lineage WNV-2a, clustering with strains circulating in Central-South-Eastern Europe and showing closest affinity to Hungarian sequences. Non-synonymous substitutions characteristic of the Hungary 578/10 ancestor (NS2B-119I, NS4B-14G, NS4B-49A and NS5-298A), were identified and absent from Central-Northern-Western European and previously reported Italian sequences. Additional substitutions (E-159T, E-399R and NS3-249P) corresponded to signatures from a fatal WNV-2 infection in a Great Grey owl in Slovakia. Conclusions: Our study provides the first report of Central-South-Eastern European WNV-2 circulation outside Eastern Europe supporting its likely spread through the Balkans into Italy by 2022. These findings underscore the rapid spread of WNV-2 in newly affected areas and highlight the critical need for sustained molecular surveillance.
Open AccessIntroduction of a European Central-South-Eastern West Nile Virus Lineage 2 strain in Italy in 2023: evidence from the first locally acquired neuroinvasive case in the Calabria region
Objective: West Nile virus lineage 2 (WNV-2) is a growing public health concern in Europe causing West Nile fever or West Nile neuroinvasive disease (WNND) with substantial morbidity and mortality; however, genomic data from Southern Italy are limited despite recent expansion of autochthonous transmission. The aim of the study was to characterise the phylogenetic and molecular features of the WNV-2 strain responsible for the first autochthonous human infection reported in Calabria (2023), and two more additional WNND cases detected in 2024. Methods: Full WNV-2 genomes were generated from the three cases. Phylogenetic analysis was performed using all publicly available WNV sequences up to September 2025. Amino-acid changes in the polyprotein were compared with known WNV-2 lineage and sub-lineage signatures. Results: The three sequences formed a monophyletic group within sub-lineage WNV-2a, clustering with strains circulating in Central-South-Eastern Europe and showing closest affinity to Hungarian sequences. Non-synonymous substitutions characteristic of the Hungary 578/10 ancestor (NS2B-119I, NS4B-14G, NS4B-49A and NS5-298A), were identified and absent from Central-Northern-Western European and previously reported Italian sequences. Additional substitutions (E-159T, E-399R and NS3-249P) corresponded to signatures from a fatal WNV-2 infection in a Great Grey owl in Slovakia. Conclusions: Our study provides the first report of Central-South-Eastern European WNV-2 circulation outside Eastern Europe supporting its likely spread through the Balkans into Italy by 2022. These findings underscore the rapid spread of WNV-2 in newly affected areas and highlight the critical need for sustained molecular surveillance.
- Open Access
- 16 December 2025
- Published by MDPI AG in Preprints.org
West Nile Virus Lineage 2 Neuroinvasive Infection Presenting as Intraparenchimal Cerebral Hemorrage
Objective: The aim of this retrospective study was to evaluate clinical and laboratory characteristics in adult patients with neuroinvasive West Nile virus (WNV) infections. We also studied the phylogeny and molecular characteristics of some of the WNV strains. Methods: A retrospective analysis was conducted at “Annunziata” Hub Hospital, a secondary referral facility in Calabria region in Southern Italy. Patients with confirmed WNV infection were included in the study. Biochemical and serological analysis of blood and cerebrospinal fluid (CSF), as well as radiological imaging were done. Sample pre-processing, sequencing and bioinformatic analyses were carried out at IRCCS Sacro Cuore Don Calabria Hospital in Negrar di Valpolicella, Verona, Veneto region in North-East Italy. All the analyses were performed on the same whole blood samples used for the laboratory diagnosis. Results: 9 cases of West Nile encephalitis (WNE) were analyzed, involving 8 males and 1 female, with a mean age of 70.33 years (Range, 60 – 85). Encephalitis was confirmed by the demonstration of specific IgM and IgG antibodies in serum using routine serological screening tests. All the patients had specific IgM antibodies at admission and IgG antibodies were present in 90%. The overall average hospital stay was 20.6 days (range, 6 – 46). Six patients made a full recovery with no neurological sequelae after a meanof 35.3days of acute care.30-day mortality rate was 23%. A 63-year-old man developed a fulminat Guillain-Barré syndrome (GBS) and he died after approximately two months because of severe respiratory complications. Two male patients died after 21 and 13 days, respectively, due to intraparenchimal cerebral hemorrage (ICH) as clinical presentation of WNV encephalitis. A third male patient presented with encephalitis and cauda equina syndrome, complicated by diffuse ICH and a concomitant extensive epidural hematoma. This patient was transferred to a rehabilitation long-term care facility and is still alive after a three-month ‘ follow-up, although he is no longer able to walk. Finally, a 66-year-old male patient presented a severe right Bell’s palsy regressing very gradually in about two months. Phylogenetic analysis shows that our sequences are closely related to other southern-Italian and cluster with Central-Southern-Eastern European sequences, while being evidently separated from northern-Italian and Central-Western European ones, belonging to the sub-lineage 2a of the WNV-2, clustering with sequences from the Central-South-Eastern clade, mainly to Hungary. Conclusions: Cerebrovascular complications of WNE may be an important clinical manifestation of WNV neuroinvasive infection. Preliminary data do not allow us to determine whether our strains, closely related to other southern-Italian and cluster with Central-Southern-Eastern European sequences, really presented an increased neurovirulence.
- 16 December 2025
- Published by MDPI AG in Preprints.org
Open AccessWest Nile Virus Lineage 2 Neuroinvasive Infection Presenting as Intraparenchimal Cerebral Hemorrage
Objective: The aim of this retrospective study was to evaluate clinical and laboratory characteristics in adult patients with neuroinvasive West Nile virus (WNV) infections. We also studied the phylogeny and molecular characteristics of some of the WNV strains. Methods: A retrospective analysis was conducted at “Annunziata” Hub Hospital, a secondary referral facility in Calabria region in Southern Italy. Patients with confirmed WNV infection were included in the study. Biochemical and serological analysis of blood and cerebrospinal fluid (CSF), as well as radiological imaging were done. Sample pre-processing, sequencing and bioinformatic analyses were carried out at IRCCS Sacro Cuore Don Calabria Hospital in Negrar di Valpolicella, Verona, Veneto region in North-East Italy. All the analyses were performed on the same whole blood samples used for the laboratory diagnosis. Results: 9 cases of West Nile encephalitis (WNE) were analyzed, involving 8 males and 1 female, with a mean age of 70.33 years (Range, 60 – 85). Encephalitis was confirmed by the demonstration of specific IgM and IgG antibodies in serum using routine serological screening tests. All the patients had specific IgM antibodies at admission and IgG antibodies were present in 90%. The overall average hospital stay was 20.6 days (range, 6 – 46). Six patients made a full recovery with no neurological sequelae after a meanof 35.3days of acute care.30-day mortality rate was 23%. A 63-year-old man developed a fulminat Guillain-Barré syndrome (GBS) and he died after approximately two months because of severe respiratory complications. Two male patients died after 21 and 13 days, respectively, due to intraparenchimal cerebral hemorrage (ICH) as clinical presentation of WNV encephalitis. A third male patient presented with encephalitis and cauda equina syndrome, complicated by diffuse ICH and a concomitant extensive epidural hematoma. This patient was transferred to a rehabilitation long-term care facility and is still alive after a three-month ‘ follow-up, although he is no longer able to walk. Finally, a 66-year-old male patient presented a severe right Bell’s palsy regressing very gradually in about two months. Phylogenetic analysis shows that our sequences are closely related to other southern-Italian and cluster with Central-Southern-Eastern European sequences, while being evidently separated from northern-Italian and Central-Western European ones, belonging to the sub-lineage 2a of the WNV-2, clustering with sequences from the Central-South-Eastern clade, mainly to Hungary. Conclusions: Cerebrovascular complications of WNE may be an important clinical manifestation of WNV neuroinvasive infection. Preliminary data do not allow us to determine whether our strains, closely related to other southern-Italian and cluster with Central-Southern-Eastern European sequences, really presented an increased neurovirulence.
- Open Access
- 24 April 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (5) , 978
First Report of Streptococcus agalactiae Meningitis in a Non-Pregnant Adult in Italy
This study, for the first time in Italy, analyses by WGS a Streptococcus agalactiae strain isolated from a non-pregnant adult affected by Meningitis and without common risk factors. The S. agalactiae strain was classified as a serotype II (SS2), sequence type ST569. Molecular characterization evidenced the presence of resistance genes to tetracycline and macrolide (tet(M) and mre(A)) and several virulence genes coding for adhesion and immune evasion factors (bca, cps family, neu family, scpB, gbs family, pil family and hylB), toxins (cfa/cfb, cyl family), pro-inflammatory factors (lepA), and two homologous genes that contributed to bacterial escape from the host immune system (lmb, luxS). SNP analysis showed 18 different alleles, with 9 missense SNP mutations related to genes involved in cellular metabolism (dhaS, ftsE, ligA, nrdD and secA), virulence (bgrR and galE) and antimicrobial resistance (glpK and mutL). SNPs in glpK and mutL genes might reduce susceptibility to drugs. The SNP analysis highlighted the presence of mutations conferring pathogenicity to the strain. The evidence in this study could explain the development of Meningitis in a healthy patient. This case highlights the importance of using molecular methods to characterize the complete genome of a bacterial species that could seriously affect human health.
- 24 April 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (5) , 978
Open AccessFirst Report of Streptococcus agalactiae Meningitis in a Non-Pregnant Adult in Italy
This study, for the first time in Italy, analyses by WGS a Streptococcus agalactiae strain isolated from a non-pregnant adult affected by Meningitis and without common risk factors. The S. agalactiae strain was classified as a serotype II (SS2), sequence type ST569. Molecular characterization evidenced the presence of resistance genes to tetracycline and macrolide (tet(M) and mre(A)) and several virulence genes coding for adhesion and immune evasion factors (bca, cps family, neu family, scpB, gbs family, pil family and hylB), toxins (cfa/cfb, cyl family), pro-inflammatory factors (lepA), and two homologous genes that contributed to bacterial escape from the host immune system (lmb, luxS). SNP analysis showed 18 different alleles, with 9 missense SNP mutations related to genes involved in cellular metabolism (dhaS, ftsE, ligA, nrdD and secA), virulence (bgrR and galE) and antimicrobial resistance (glpK and mutL). SNPs in glpK and mutL genes might reduce susceptibility to drugs. The SNP analysis highlighted the presence of mutations conferring pathogenicity to the strain. The evidence in this study could explain the development of Meningitis in a healthy patient. This case highlights the importance of using molecular methods to characterize the complete genome of a bacterial species that could seriously affect human health.
- Open Access
- 4 March 2025
- Published by MDPI AG in Preprints.org
First Report of Streptococcus agalactiae Meningitis in a Non-Pregnant Adult in Italy
This study, for the first time in Italy, analyses by WGS a Streptococcus agalactiae strain isolated from a non-pregnant adult affected by meningitis and without common risk factors. The S. agalactiae strain was classified as a serotype II (SS2), sequence type ST569. Molecular characterization evidenced the presence of resistance genes to tetracycline and macrolide (tet(M) and mre(A)) and several virulence genes coding for adhesion and immune evasion factors (bca, cps family, neu family, scpB, gbs family, pil family and hylB), toxins (cfa/cfb, cyl family), pro-inflammatory factors (lepA), and two homologous genes that contributed to bacterial escape from the host immune system (lmb, luxS). SNPs analysis showed 18 different alleles, with 9 missense SNP mutations related to genes involved in cellular metabolism (dhaS, ftsE, ligA, nrdD and secA), virulence (bgrR and galE) and antimicrobial resistance (glpK and mutL). SNPs in glpK and mutL genes might reduce susceptibility to drugs. The SNPs analysis highlighted the presence of mutations conferring pathogenicity to the strain. The evidence in this study could explain the development of meningitis in a healthy patient. This case highlights the importance of using molecular methods to characterize the complete genome of a bacterial species that could seriously affect human health.
- 4 March 2025
- Published by MDPI AG in Preprints.org
Open AccessFirst Report of Streptococcus agalactiae Meningitis in a Non-Pregnant Adult in Italy
This study, for the first time in Italy, analyses by WGS a Streptococcus agalactiae strain isolated from a non-pregnant adult affected by meningitis and without common risk factors. The S. agalactiae strain was classified as a serotype II (SS2), sequence type ST569. Molecular characterization evidenced the presence of resistance genes to tetracycline and macrolide (tet(M) and mre(A)) and several virulence genes coding for adhesion and immune evasion factors (bca, cps family, neu family, scpB, gbs family, pil family and hylB), toxins (cfa/cfb, cyl family), pro-inflammatory factors (lepA), and two homologous genes that contributed to bacterial escape from the host immune system (lmb, luxS). SNPs analysis showed 18 different alleles, with 9 missense SNP mutations related to genes involved in cellular metabolism (dhaS, ftsE, ligA, nrdD and secA), virulence (bgrR and galE) and antimicrobial resistance (glpK and mutL). SNPs in glpK and mutL genes might reduce susceptibility to drugs. The SNPs analysis highlighted the presence of mutations conferring pathogenicity to the strain. The evidence in this study could explain the development of meningitis in a healthy patient. This case highlights the importance of using molecular methods to characterize the complete genome of a bacterial species that could seriously affect human health.
- Open Access
- 26 January 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (2) , 128
Circulation of a Unique Klebsiella pneumoniae Clone, ST147 NDM-1/OXA-48, in Two Diverse Hospitals in Calabria (Italy)
Background/Objectives: Carbapenem-resistant Klebsiella pneumoniae has become endemic in Europe, including in Italy, where its prevalence has risen dramatically, primarily due to epidemic clones harboring metallo-enzymes. This study aims to investigate the dissemination of K. pneumoniae strains co-producing OXA-48 and NDM-1 between two hospitals in southern Italy using molecular analyses. Methods: A total of 49 K. pneumoniae strains, predominantly co-producing OXA-48 and NDM-1, were collected between March and December 2023. Antibiotic susceptibility testing was conducted following EUCAST guidelines. Whole-genome sequencing (Illumina MiSeq) and bioinformatics tools (CARD, CLC Genomics Workbench) were used to identify resistance and virulence genes, capsule loci, and phylogenetic relationships. Results: All isolates exhibited multidrug-resistant or extensively drug-resistant profiles, including resistance to ceftazidime/avibactam and meropenem/vaborbactam. Genomic analysis revealed diverse resistance genes such as blaOXA-48, blaNDM-1, blaCTX-M-15, and blaSHV variants. Virulence genes associated with capsules, fimbriae, and siderophores were widespread. Most strains were classified as ST147 by MLST and contained various plasmids known to carry antimicrobial resistance. Phylogenetic analysis confirmed their clonal relatedness, highlighting the intra-hospital dissemination of high-risk clones. Conclusions: High-risk K. pneumoniae clones, particularly ST147, pose significant challenges in healthcare settings due to the extensive antimicrobial resistance driven by plasmid-borne resistance genes, including those that co-produce carbapenemases, like blaNDM-1 and blaOXA-48. Molecular monitoring of these clones is essential for improving targeted infection control strategies, mitigating the spread of multidrug-resistant pathogens, and managing their clinical impact effectively.
- 26 January 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (2) , 128
Open AccessCirculation of a Unique Klebsiella pneumoniae Clone, ST147 NDM-1/OXA-48, in Two Diverse Hospitals in Calabria (Italy)
Background/Objectives: Carbapenem-resistant Klebsiella pneumoniae has become endemic in Europe, including in Italy, where its prevalence has risen dramatically, primarily due to epidemic clones harboring metallo-enzymes. This study aims to investigate the dissemination of K. pneumoniae strains co-producing OXA-48 and NDM-1 between two hospitals in southern Italy using molecular analyses. Methods: A total of 49 K. pneumoniae strains, predominantly co-producing OXA-48 and NDM-1, were collected between March and December 2023. Antibiotic susceptibility testing was conducted following EUCAST guidelines. Whole-genome sequencing (Illumina MiSeq) and bioinformatics tools (CARD, CLC Genomics Workbench) were used to identify resistance and virulence genes, capsule loci, and phylogenetic relationships. Results: All isolates exhibited multidrug-resistant or extensively drug-resistant profiles, including resistance to ceftazidime/avibactam and meropenem/vaborbactam. Genomic analysis revealed diverse resistance genes such as blaOXA-48, blaNDM-1, blaCTX-M-15, and blaSHV variants. Virulence genes associated with capsules, fimbriae, and siderophores were widespread. Most strains were classified as ST147 by MLST and contained various plasmids known to carry antimicrobial resistance. Phylogenetic analysis confirmed their clonal relatedness, highlighting the intra-hospital dissemination of high-risk clones. Conclusions: High-risk K. pneumoniae clones, particularly ST147, pose significant challenges in healthcare settings due to the extensive antimicrobial resistance driven by plasmid-borne resistance genes, including those that co-produce carbapenemases, like blaNDM-1 and blaOXA-48. Molecular monitoring of these clones is essential for improving targeted infection control strategies, mitigating the spread of multidrug-resistant pathogens, and managing their clinical impact effectively.